Vertex, Inc. (VERX)

KING OF PRUSSIA, Pa., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of indirect tax solutions, today announced the launch of Kintsugi powered by Vertex, a new AI-native tax automation solution developed in partnership with Kintsugi, a fast-growing startup focused on transforming tax compliance for SMB's through intelligent automation.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2025 Earnings Call.” The conference call will be webcast live and a link to the webcast ca.

KING OF PRUSSIA, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release third quarter 2025 financial results before the market opens on Monday, November 3, 2025. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day.

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three key drugs, Trikafta, Kaftrio, and Alyftrek, which are part of the CF portfolio, reached about $2.71 billion in the second quarter of 2025, up 10.6% year-on-year. On the positive side, Vertex's operating income margin, which was 38.9% for the three months ended June 30, 2025, is higher than that of its competitors, including Pfizer and Sarepta.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). These updates represent significant progress toward reaching the Company's goal of bringing forward first-in-class or best-in-class therapies that target the underlying cause of these serious kidney diseases. Povetacicept.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults and the first new class of pain medicine approved in more than 20 years. During the 2025 playoffs in May, Jayson ruptured his Achilles tendon, a season-ending injury that required immediate.

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with.

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (.

The Investment Committee discuss the latest Calls of the Day.

As 85% of consumers begin summer shopping in late winter, businesses face a new peak season – and a growing need for automated tax technology to manage product complexity and compliance As 85% of consumers begin summer shopping in late winter, businesses face a new peak season – and a growing need for automated tax technology to manage product complexity and compliance

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 11:00 a.m. ET. Reshma Kewalramani, President and Chief Executive Officer, and Duncan McKechnie, Executive Vice P.

Vertex Pharmaceuticals (VRTX 0.17%) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process.

This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear growth catalysts for 2025 and beyond. Caution is urged on popular income-focused ETFs like SPYI and ULTY, as structural flaws and capped upside may limit long-term wealth compounding.

I downgrade Vertex (VERX) to Hold due to macro headwinds and ERP migration delays impacting near-term growth outlook. Cloud momentum and e-invoicing adoption remain strong, but on-premise weakness and slower customer expansion weigh on results. FY25 guidance was cut, and growth reacceleration is now less certain, resetting investor expectations and hurting sentiment.